Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer

Kenji Nemoto; Haruo Matsushita; Yoshihiro Ogawa; Ken Takeda; Chiaki Takahashi; Keith R. Britton; Yoshihiro Takai; Shukichi Miyazaki; Tsuyoshi Miyata; Shogo Yamada

doi:10.1097/00000421-200302000-00010

Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer

Kenji Nemoto, Haruo Matsushita, Yoshihiro Ogawa, Ken Takeda, Chiaki Takahashi, Keith R. Britton, Yoshihiro Takai, Shukichi Miyazaki, Tsuyoshi Miyata, Shogo Yamada

MED - Health Sciences

Tohoku University

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days). Grade III leukocytopenia was observed in 6 (25%) of the patients. Grade III and IV thrombocytopenia was observed in one patient each. The 1-year and 2-year survival rates for definitively irradiated patients were 59% and 39%, respectively, and for patients with postoperative recurrence 69% and 69%, respectively. High-dose radiation combined with Nedaplatin and 5-FU is a safe and effective method for treating esophageal cancer.

Original language	English
Pages (from-to)	46-49
Number of pages	4
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	26
Issue number	1
DOIs	https://doi.org/10.1097/00000421-200302000-00010
Publication status	Published - 2003 Feb

Keywords

5-FU
Chemotherapy
Esophageal cancer
Nedaplatin
Radiation therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-200302000-00010

Cite this

Nemoto, K., Matsushita, H., Ogawa, Y., Takeda, K., Takahashi, C., Britton, K. R., Takai, Y., Miyazaki, S., Miyata, T., & Yamada, S. (2003). Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 26(1), 46-49. https://doi.org/10.1097/00000421-200302000-00010

@article{367203cf64a94694a6abf5b873914c80,

title = "Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer",

abstract = "From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days). Grade III leukocytopenia was observed in 6 (25%) of the patients. Grade III and IV thrombocytopenia was observed in one patient each. The 1-year and 2-year survival rates for definitively irradiated patients were 59% and 39%, respectively, and for patients with postoperative recurrence 69% and 69%, respectively. High-dose radiation combined with Nedaplatin and 5-FU is a safe and effective method for treating esophageal cancer.",

keywords = "5-FU, Chemotherapy, Esophageal cancer, Nedaplatin, Radiation therapy",

author = "Kenji Nemoto and Haruo Matsushita and Yoshihiro Ogawa and Ken Takeda and Chiaki Takahashi and Britton, {Keith R.} and Yoshihiro Takai and Shukichi Miyazaki and Tsuyoshi Miyata and Shogo Yamada",

year = "2003",

month = feb,

doi = "10.1097/00000421-200302000-00010",

language = "English",

volume = "26",

pages = "46--49",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "1",

}

Nemoto, K, Matsushita, H, Ogawa, Y, Takeda, K, Takahashi, C, Britton, KR, Takai, Y, Miyazaki, S, Miyata, T & Yamada, S 2003, 'Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 26, no. 1, pp. 46-49. https://doi.org/10.1097/00000421-200302000-00010

Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. / Nemoto, Kenji; Matsushita, Haruo; Ogawa, Yoshihiro et al.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 1, 02.2003, p. 46-49.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer

AU - Nemoto, Kenji

AU - Matsushita, Haruo

AU - Ogawa, Yoshihiro

AU - Takeda, Ken

AU - Takahashi, Chiaki

AU - Britton, Keith R.

AU - Takai, Yoshihiro

AU - Miyazaki, Shukichi

AU - Miyata, Tsuyoshi

AU - Yamada, Shogo

PY - 2003/2

Y1 - 2003/2

N2 - From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days). Grade III leukocytopenia was observed in 6 (25%) of the patients. Grade III and IV thrombocytopenia was observed in one patient each. The 1-year and 2-year survival rates for definitively irradiated patients were 59% and 39%, respectively, and for patients with postoperative recurrence 69% and 69%, respectively. High-dose radiation combined with Nedaplatin and 5-FU is a safe and effective method for treating esophageal cancer.

AB - From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days). Grade III leukocytopenia was observed in 6 (25%) of the patients. Grade III and IV thrombocytopenia was observed in one patient each. The 1-year and 2-year survival rates for definitively irradiated patients were 59% and 39%, respectively, and for patients with postoperative recurrence 69% and 69%, respectively. High-dose radiation combined with Nedaplatin and 5-FU is a safe and effective method for treating esophageal cancer.

KW - 5-FU

KW - Chemotherapy

KW - Esophageal cancer

KW - Nedaplatin

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0037318945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037318945&partnerID=8YFLogxK

U2 - 10.1097/00000421-200302000-00010

DO - 10.1097/00000421-200302000-00010

M3 - Article

C2 - 12576924

AN - SCOPUS:0037318945

SN - 0277-3732

VL - 26

SP - 46

EP - 49

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 1

ER -

Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this